Interdependency Between TP53 Mutations, Cytogenetics, Genetic Instability and Prognosis in MDS and Secondary AML

被引：0

作者：

Schaab, Roxana ^{[1
]}

Ganster, Christina ^{[1
]}

Dierks, Sascha ^{[1
]}

Shirneshan, Katayoon ^{[1
]}

Parra, Marc Tallo ^{[1
]}

Martin, Roman ^{[1
]}

Germing, Ulrich ^{[2
]}

Platzbecker, Uwe ^{[3
]}

Lange, Frank ^{[4
]}

Kroeger, Nicolaus ^{[5
]}

Dohner, Konstanze ^{[6
]}

Glass, Bertram ^{[7
]}

Nickelsen, Maike ^{[7
]}

Stuhlmann, Reingard ^{[8
]}

Truemper, Lorenz H. ^{[1
]}

Schanz, Julie ^{[1
]}

Bacher, Ulrike ^{[9
]}

Haase, Detlef ^{[1
]}

机构：

[1] Univ Gottingen, Dept Hematol & Med Oncol, Gottingen, Germany

[2] Univ Dusseldorf, Dept Hematol Oncol & Clin Immunol, Dusseldorf, Germany

[3] Carl Gustav Carus Tech Univ, Univ Klinikum, Dresden, Germany

[4] Hufeland Klinikum, Muhlhausen, Germany

[5] Univ Med Ctr Hamburg Eppendorf, Dept Stem Cell Transplantat, Hamburg, Germany

[6] Univ Hosp Ulm, Dept Internal Med 3, Ulm, Germany

[7] Asklepios Hosp St Georg, Hematol Oncol & Stem Cell Transplantat, Hamburg, Germany

[8] Onkolog Schwerpunktpraxis, Dannenberg, Germany

[9] Med Ctr Univ Gottingen, Dept Hematol & Med Oncol, Gottingen, Germany

来源：

BLOOD | 2016年 / 128卷 / 22期

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

2001

引用

页数：6

共 50 条

[1] Interdependency between TP53 mutational status, genetic instability and prognosis in MDS and secondary AML
Schaab, R.
Ganster, C.
Dierks, S.
Parra, Tallo M.
Martin, R.
Germing, U.
Platzbecker, U.
Shirneshan, K.
Lange, F.
Kroeger, N.
Doehner, K.
Glass, B.
Bacher, U.
Haase, D.
ONCOLOGY RESEARCH AND TREATMENT, 2016, 39 : 236 - 236
[2] Isolated TP53 Mutations Portend Worse Prognosis in MDS and AML Compared to TP53 Mutations with Concurrent Myeloid-Associated Mutations
Hussaini, Mohammad
Abuel-Haija, Mohammad
Padron, Eric
David, Sallman
Song, Jinming
MODERN PATHOLOGY, 2018, 31 : 524 - 525
[3] Isolated TP53 Mutations Portend Worse Prognosis in MDS and AML Compared to TP53 Mutations with Concurrent Myeloid-Associated Mutations
Hussaini, Mohammad
Abuel-Haija, Mohammad
Padron, Eric
David, Sallman
Song, Jinming
LABORATORY INVESTIGATION, 2018, 98 : 524 - 525
[4] The impact of TP53 mutations and TP53 deletions on survival varies between AML, ALL, MDS and CLL: an analysis of 3307 cases
A Stengel
W Kern
T Haferlach
M Meggendorfer
A Fasan
C Haferlach
Leukemia, 2017, 31 : 705 - 711
[5] The impact of TP53 mutations and TP53 deletions on survival varies between AML, ALL, MDS and CLL: an analysis of 3307 cases
Stengel, A.
Kern, W.
Haferlach, T.
Meggendorfer, M.
Fasan, A.
Haferlach, C.
LEUKEMIA, 2017, 31 (03) : 705 - 711
[6] Is TP53 Mutated AML the Same Disease as TP53 Mutated MDS?
Valk, Peter J. M.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S3 - S5
[7] TP53 in MDS and AML: Biological and clinical advances
Zhao, Yeqian
Chen, Weihao
Yu, Jing
Pei, Shanshan
Zhang, Qiang
Shi, Jimin
Huang, He
Zhao, Yanmin
CANCER LETTERS, 2024, 588
[8] TP53 mutations and MDS - not as easy as it seems
Haase, D.
ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 (SUPPL 4) : 7 - 8
[9] Patterns of mutations in TP53 mutated AML
Welch, John S.
BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY, 2018, 31 (04) : 379 - 383
[10] Pathogenic TP53 mutations Are Associated with a Poor Prognosis in De Novo AML
Lamble, Adam J.
Ries, Rhonda E.
Dang, Alice
Alonzo, Todd A.
Chisholm, Karen
Kolekar, Pandurang
Liu, Yanling
Tran, Quang
Cooper, Todd M.
Aplenc, Richard
Gamis, Alan S.
Kolb, Edward A.
Ma, Xiaotu
Meshinchi, Soheil
BLOOD, 2022, 140 : 6297 - 6298

← 1 2 3 4 5 →